Meiragtx Holdings Plc

Meiragtx Holdings Plc

Meiragtx Holdings Plc

Overview
Date Founded

2015

Headquarters

430 East 29th Street, 10th Floor, New York, NY, 10016, USA

Type of Company

Public

Employees (Worldwide)

68

Industries

Biotechnology

Company Description

MeiraGTx Holdings Plc is a clinical-stage biotech company, which engages in the development of novel gene therapy treatments. It operates through the United States and United Kingdom geographical segments. Its pipeline includes AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Executives & Employees

President, Chief Executive Officer & Director

Chief Financial Officer

Chief Development Officer

Board of Directors

Co-Founder at Alexandria Real Estate Equities, Inc.

Former Corporate Executive Officer at Sony Corporation of America

Founder at FORGE Life Science LLC

Distinguished Fellow at Council on Foreign Relations

Co-Founder at PMV Pharmaceuticals, Inc.

Managing Director at Perceptive Advisors LLC

President, Chief Executive Officer & Director at Meiragtx Holdings Plc

Executive Chairman at SAPO Plc

Paths to Meiragtx Holdings Plc
Potential Connections via
Relationship Science
You
Meiragtx Holdings Plc
Owners & Shareholders
Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

Founded in 2008, Prosight Management LP is a hedge fund manager located in Dallas, Texas. The firm also does business as Prosight Capital. They manage the Prosight Fund LP.

Recent Transactions
Details Hidden

Meiragtx Holdings Plc issued USD Ordinary Shares

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onMeiragtx Holdings Plc issued USD Ordinary Shares

Underwriter

Advised onMeiragtx Holdings Plc issued USD Ordinary Shares

Escrow Agent

Advised onMeiragtx Holdings Plc issued USD Ordinary Shares

Legal Advisor

Advised onMeiragtx Holdings Plc issued USD Ordinary Shares

Legal Advisor

Advised onMeiragtx Holdings Plc issued USD Ordinary Shares

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Key Stats and Financials As of 2018
Market Capitalization
$670M
Total Enterprise Value
$115M
Earnings Per Share
$-4.47
Revenue
$0
Total Equity
$81.1M
Total Debt
$34.3K
EBITDA
$-76.1M
Net Profit
$-82.9M
TEVNet Income
-1.38x
Debt TEV
0x
Investors
Details Hidden

Perceptive Advisors invests in health care technology companies located in the US. The firm provides financing for early stage requirements and their AUM is $3 billion.

Suppliers
Brandeis University Schools & Student Services | Waltham, MA

Brandeis University is an American private research university with a liberal arts focus. It is located in Waltham, Massachusetts, 9 miles (14 km) west of Boston. The university has an enrollment of approximately 3,600 undergraduate and 2,200 graduate students.[4] It was tied for 32nd among national universities in the United States in U.S. News & World Report 's 2014 rankings. Forbes listed Brandeis University as number 51 among all national universities and liberal arts colleges combined in 2013. Brandeis was founded in 1948 as a nonsectarian Jewish community-sponsored coeducational institution on the site of the former Middlesex University. The university is named for Louis Brandeis (1856–1941), the first Jewish Justice of the Supreme Court of the United States.

Cornell University Computer Software | Ithaca, New York

Cornell is a privately endowed research university and a partner of the State University of New York. As the federal land-grant institution in New York State, they have a responsibility—unique within the Ivy League—to make contributions in all fields of knowledge in a manner that prioritizes public engagement to help improve the quality of life in our state, the nation, the world.

University College London London, United Kingdom

University College London (UCL) is a public research university in London, England, and the oldest and largest constituent college of the federal University of London. Founded in 1826 as London University, UCL was the first university institution established in London and the first in England to be entirely secular, to admit students regardless of their religion, and to admit women on equal terms with men. The philosopher Jeremy Bentham is commonly regarded as the spiritual father of UCL, as his radical ideas on education and society were the inspiration to its founders, although his direct involvement in its foundation was limited. UCL became one of the two founding colleges of the University of London in 1836. It has grown through mergers, including with the Institute of Neurology (in 1997), the Royal Free Hospital Medical School (in 1998), the Eastman Dental Institute (in 1999), the School of Slavonic and East European Studies (in 1999) and the School of Pharmacy (in 2012). UCL's main campus is located in the Bloomsbury area of central London, with a number of institutes and teaching hospitals located elsewhere in central London, and satellite campuses in Adelaide, Australia and Doha, Qatar. UCL is organised into 10 constituent faculties, within which there are over 100 departments, institutes and research centres. UCL has around 26,700 students and 11,025 staff and had a total income of £937 million in 2012/13, of which £335 million was from research grants and contracts. UCL has around 4,000 academic and research staff and 650 full professors, the highest number of any British university. UCL is responsible for several museums and collections in a wide range of fields across the arts and sciences, including the Petrie Museum of Egyptian Archaeology, a leading collection of Egyptian and Sudanese archaeology.

Competitors
Biogen, Inc. Biotechnology - San Diego, CA

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Applied Genetic Technologies Corp. Pharmaceuticals - Alachua, Florida

Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Meiragtx Holdings Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Meiragtx Holdings Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Meiragtx Holdings Plc.